

**Format:** Abstract**Full text links**Int J Neurosci. 1986 Nov;30(4):277-82.

## Open label evaluation of cannabidiol in dystonic movement disorders.

Consroe P, Sandyk R, Snider SR.

### Abstract

Cannabidiol (CBD), a nonpsychoactive cannabinoid of Cannabis, was given to 5 patients with dystonic movement disorders in a preliminary open pilot study. Oral doses of CBD rising from 100 to 600 mg/day over a 6 week period were administered along with standard medication. Dose-related improvement in dystonia was observed in all patients and ranged from 20 to 50%. Side-effects of CBD were mild and included hypotension, dry mouth, psychomotor slowing, lightheadedness, and sedation. In 2 patients with coexisting Parkinsonian features, CBD at doses over 300 mg/day exacerbated the hypokinesia and resting tremor. CBD appears to have antidystonic and Parkinsonism-aggravating effects in humans.

PMID: 3793381 DOI: [10.3109/00207458608985678](https://doi.org/10.3109/00207458608985678)

[Indexed for MEDLINE]

**Publication types, MeSH terms, Substances, Grant support** **LinkOut - more resources** **Full Text Sources**[Taylor & Francis](#)**Other Literature Sources**[Cited by Patents in - The Lens](#)**Medical**[Dystonia - MedlinePlus Health Information](#)